These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

698 related items for PubMed ID: 30597611

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Effectiveness and safety of rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation and coronary or peripheral artery disease.
    Coleman CI, Baker WL, Meinecke AK, Eriksson D, Martinez BK, Bunz TJ, Alberts MJ.
    Eur Heart J Cardiovasc Pharmacother; 2020 Jul 01; 6(3):159-166. PubMed ID: 31549153
    [Abstract] [Full Text] [Related]

  • 5. Rivaroxaban Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation and Severe Kidney Disease or Undergoing Hemodialysis.
    Coleman CI, Kreutz R, Sood NA, Bunz TJ, Eriksson D, Meinecke AK, Baker WL.
    Am J Med; 2019 Sep 01; 132(9):1078-1083. PubMed ID: 31054829
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Frail Patients With Nonvalvular Atrial Fibrillation.
    Martinez BK, Sood NA, Bunz TJ, Coleman CI.
    J Am Heart Assoc; 2018 Apr 13; 7(8):. PubMed ID: 29654196
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Effectiveness and Safety of Rivaroxaban versus Warfarin Among Nonvalvular Atrial Fibrillation Patients with Obesity and Polypharmacy.
    Alberts MJ, He J, Kharat A, Ashton V.
    Am J Cardiovasc Drugs; 2022 Jul 13; 22(4):425-436. PubMed ID: 35092000
    [Abstract] [Full Text] [Related]

  • 11. Rivaroxaban Versus Warfarin in African American Patients with Nonvalvular Atrial Fibrillation.
    Coleman CI, Thompson S, Ashton V, Palladino M, Bunz TJ.
    J Natl Med Assoc; 2020 Aug 13; 112(4):395-401. PubMed ID: 32493618
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Dose specific effectiveness and safety of DOACs in patients with non-valvular atrial fibrillation: A Canadian retrospective cohort study.
    Rahme E, Godin R, Nedjar H, Dasgupta K, Tagalakis V.
    Thromb Res; 2021 Jul 13; 203():121-130. PubMed ID: 34000493
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 35.